Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT

The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning, related donor hematopoietic cell transplantation (HCT). However, its safety and efficacy in preventing acute GVHD in setting...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Choi, Sung Won, Braun, Thomas, Henig, Israel, Gatza, Erin, Magenau, John, Parkin, Brian, Pawarode, Attaphol, Riwes, Mary, Yanik, Greg, Dinarello, Charles A., Reddy, Pavan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5639486/
https://ncbi.nlm.nih.gov/pubmed/28784598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-790469
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados